Mathematical modeling of developmental signaling networks has played an increasingly important role in the identification of regulatory mechanisms by providing a sandbox for hypothesis testing and experiment design. Whether these models consist of an equation with a few parameters or dozens of equations with hundreds of parameters, a prerequisite to model-based discovery is to bring simulated behavior into agreement with observed data via parameter estimation. These parameters provide insight into the system (e.g., enzymatic rate constants describe enzyme properties). Depending on the nature of the model fit desired - from qualitative (relative spatial positions of phosphorylation) to quantitative (exact agreement of spatial position and concentration of gene products) - different measures of data-model mismatch are used to estimate different parameter values, which contain different levels of usable information and/or uncertainty. To facilitate the adoption of modeling as a tool for discovery alongside other tools such as genetics, immunostaining, and biochemistry, careful consideration needs to be given to how well a model fits the available data, what the optimized parameter values mean in a biological context, and how the uncertainty in model parameters and predictions plays into experiment design. The core discussion herein pertains to the quantification of model-to-data agreement, which constitutes the first measure of a model's performance and future utility to the problem at hand. Integration of this experimental data and the appropriate choice of objective measures of data-model agreement will continue to drive modeling forward as a tool that contributes to experimental discovery. The Drosophila melanogaster gap gene system, in which model parameters are optimized against in situ immunofluorescence intensities, demonstrates the importance of error quantification, which is applicable to a wide array of developmental modeling studies.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4378650 | PMC |
http://dx.doi.org/10.1016/j.semcdb.2014.06.017 | DOI Listing |
Eval Rev
January 2025
Global Development Network, Lanzhou University and Director of Evaluation, New Delhi, India.
Official development agencies are increasingly supporting civil society lobby and advocacy (L&A) to address poverty and human rights. However, there are challenges in evaluating L&A. As programme objectives are often to change policies or practices in a single institution like a Government Ministry, L&A programmes are often not amenable to large-n impact evaluation methods.
View Article and Find Full Text PDFHum Exp Toxicol
January 2025
Department of Gynecology and Obstetrics, Fuyong People's Hospital, Shenzhen, China.
Gestational diabetes mellitus (GDM) is a metabolic disorder that arises during pregnancy and heightens the risk of placental dysplasia. Ginsenoside Re (Re) may stabilize insulin and glucagon to regulate glucose levels, which may improve diabetes-associated diseases. This study aims to investigate the mechanism of Re in high glucose (HG)-induced apoptosis of trophoblasts through endoplasmic reticulum stress (ERS)-related protein CHOP/GADD153.
View Article and Find Full Text PDFClin Rheumatol
January 2025
Department of Pediatric Rheumatology, Zeynep Kamil Women and Children's Diseases Training and Research Hospital, Istanbul, Turkey.
Ann Intensive Care
January 2025
Department of Intensive Care Medicine, Universitaire Ziekenhuis Brussel (UZ Brussel), Vrije Universiteit Brussel (VUB), Brussels, Belgium.
Background: Continuous veno-venous hemodiafiltration (CVVHDF) is used in critically ill patients, but its impact on O₂ and CO₂ removal, as well as the accuracy of resting energy expenditure (REE) measurement using indirect calorimetry (IC) remains unclear. This study aims to evaluate the effects of CVVHDF on O₂ and CO₂ removal and the accuracy of REE measurement using IC in patients undergoing continuous renal replacement therapy.
Design: Prospective, observational, single-center study.
Pharmacoeconomics
January 2025
Belgian Health Care Knowledge Centre, Brussels, Belgium.
Background: Forecasting future public pharmaceutical expenditure is a challenge for healthcare payers, particularly owing to the unpredictability of new market introductions and their economic impact. No best-practice forecasting methods have been established so far. The literature distinguishes between the top-down approach, based on historical trends, and the bottom-up approach, using a combination of historical and horizon scanning data.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!